Ask VialBase
Retrospective observational study · PMID 41938643

Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study — VialBase Research

All three GLP-1 RAs produced significant weight loss and waist circumference reduction at 36 weeks

Last updated · 2026 · Cetiner S · Diabetes, Metabolic Syndrome and Obesity
Key findings
  • All three GLP-1 RAs produced significant weight loss and waist circumference reduction at 36 weeks
  • Tirzepatide showed greatest weight loss among the three agents
  • GI adverse events were most common with liraglutide
  • No clinically confirmed pancreatitis in any group
  • Liver enzyme improvements observed across all groups

PMID 41938643 — Real-World GLP-1 RA Comparison

Compound: Liraglutide Citation: Cetiner S. Diabetes Metab Syndr Obes. 2026;19:594898. doi:10.2147/DMSO.S594898

Summary

Single-center retrospective study in Istanbul comparing liraglutide, semaglutide, and tirzepatide in adults with overweight/obesity without diabetes who received treatment for at least 36 weeks.

Key Results

  • All three agents effective for weight loss and waist circumference reduction (P < 0.01)
  • Tirzepatide > semaglutide > liraglutide for weight loss magnitude
  • Greater triglyceride reduction with tirzepatide
  • Similar liver enzyme improvements across groups
  • GI adverse events most common with liraglutide (nausea, vomiting, diarrhea)
  • No confirmed pancreatitis cases

Clinical Implications

Confirms liraglutide’s position as effective but less potent than newer agents. GI tolerability may be lower than semaglutide/tirzepatide. Useful real-world data complementing RCTs.

PubMed

See Also

View on PubMed · PMID 41938643 →